Clinical Stage Partnerships Clinical-stage immuno-oncology platform with a glioblastoma focus creates opportunities for collaboration with CROs and larger pharma to advance multi-site brain tumor trials and accelerate patient access.

Manufacturing Scale-Up A leadership emphasis on manufacturing signals a scale-up trajectory for viral immunotherapies, creating opportunities to engage CMOs and contract manufacturers for viral vector production, fill-finish, and supply-chain support.

Academic Network Access Proximity to Duke University and the founders' strong academic networks enable access to neurosurgical and oncology trial sites, patient registries, and translational research collaborations that can speed enrollment.

Indication Expansion Licensing The LUMINOS-103 basket trial and broad solid-tumor focus point to potential licensing or co-development deals with partners seeking immunotherapy assets for additional indications such as bladder cancer.

Regulatory Partnerships A combination of published research and industry recognition suggests Istari is well-positioned to attract regulatory, safety, and data-management partnerships that de-risk development and facilitate outreach to potential partners.